Gain Clarity from European Regulatory Expectations to Advance Innovative Biomarker & Diagnostic-Driven Therapies Towards the Clinic with Optimized Market Access & Patient Adoption

The highly anticipated 12th Clinical Biomarkers & CDx Summit Europe will return in 2022 as Europe’s only end-to-end clinical biomarker and companion diagnostics summit bringing you the latest intelligence to reinvigorate your precision medicine strategy.

As the field witnesses greater numbers of exciting Drug-Dx approvals being driven by major advancements in biomarker development, the CB & CDx event sets the stage for key learnings with exclusive data to you optimize your drug development programs in precision medicine from start to finish.

Against the backdrop of complex regulatory changes creating industry-wide uncertainty, now more than ever before it’s important you unite with 300+ Precision Medicine, Biomarker & Diagnostic experts. This timely forum, which combines a mix of workshops, formal presentations, panels, live tech demos, networking & collaborative discussion, is your only summit to build the foundation for successful and regulatory adherent collaborations for 2022 & beyond!

Delving deep into the most ground-breaking work enabling patient population identification, and pairing this with revelations from cutting-edge commercial strategies, this is an industry poised to gain actionable insights maximising access to game-changing precision medicines and testing technology.

Agenda launching soon – register your interest to attend now!

Content & Discussions Not to Miss: Agenda at a Glance



Plenary Stage

Designed for the entire value chain of precision drug development


Clinical Biomarker Development Stream

Designed for preclinical, translational & clinical leaders

Drug-Dx Commercialization Stream

Designed for regulatory, precision medicine, CDx & commercial leaders

  • Plan your next clinical & portfolio steps facing incoming IVDR
  • Discover targeted therapy end-to-end Drug-Dx co-development case studies
  • Hear how precision medicine is being implemented beyond oncology
  • Learn how the landscape is changing with reverberating Covid-19 impacts and digital biomarker improvements


  • Discover biomarkers to predict response applying latest genomic-based testing technology
  • Harness liquid-based biomarker testing technology to unpick heterogeneity and see faster enrolment
  • Define your predictive biomarker strategy to shorten clinical timeframes
  • Generate comprehensive biomarker read-outs with robust bioanalytical validation


  • Identify global trends in CDx development to strategically plan your precision medicine portfolio
  • Create and implement CDx strategies to bring innovative therapies to the clinic
  • Effectively collaborate to maximise Drug-Dx access to launch
  • Work with community counterparts to navigate a complex testing landscape in Europe


Expert Speakers Who Joined in 2021 Included:

Hear What Our Attendees Say

“Fantastic organisation along with facilitation of effective networking. Conference content well thought through covering major discussion points within the field of Companion Diagnostics & Clinical Biomarkers.”

MiNA Therapeutics

“It was great as ever, both from content as well as networking opportunity. The Hanson Wade Team has again done a great job.”


“The Hansonwade team are really on the ball when it comes to customer service, industry insights and understanding what makes an event work.  Great location this year and look forward to the next event!”


Other Events in the Series